Article

Incidence of intracranial hemorrhage in patients with atrial fibrillation who are prone to fall

Yale University, New Haven, Connecticut, United States
The American Journal of Medicine (Impact Factor: 5.3). 07/2005; 118(6):612-7. DOI: 10.1016/j.amjmed.2005.02.022
Source: PubMed

ABSTRACT Patients at high risk for falls are presumed to be at increased risk for intracranial hemorrhage, and high risk for falls is cited as a contraindication to antithrombotic therapy. Data substantiating this concern are lacking.
Quality improvement organizations identified 1245 Medicare beneficiaries who were documented in the medical record to be at high risk of falls and 18261 other patients with atrial fibrillation. The patients were elderly (mean 80 years), and 48% were prescribed warfarin at hospital discharge. The primary endpoint was subsequent hospitalization for an intracranial hemorrhage, based on ICD-9 codes.
Rates (95% confidence interval [CI]) of intracranial hemorrhage per 100 patient-years were 2.8 (1.9-4.1) in patients at high risk for falls and 1.1 (1.0-1.3) in other patients. Rates (95% CI) of traumatic intracranial hemorrhage were 2.0 (1.3-3.1) in patients at high risk for falls and 0.34 (0.27-0.45) in other patients. Hazard ratios (95% CI) of other independent risk factors for intracranial hemorrhage were 1.4 (1.0-3.1) for neuropsychiatric disease, 2.1 (1.6-2.7) for prior stroke, and 1.9 (1.4-2.4) for prior major bleeding. Warfarin prescription was associated with intracranial hemorrhage mortality but not with intracranial hemorrhage occurrence. Ischemic stroke rates per 100 patient-years were 13.7 in patients at high risk for falls and 6.9 in other patients. Warfarin prescription in patients prone to fall who had atrial fibrillation and multiple additional stroke risk factors appeared to protect against a composite endpoint of stroke, intracranial hemorrhage, myocardial infarction, and death.
Patients at high risk for falls with atrial fibrillation are at substantially increased risk of intracranial hemorrhage, especially traumatic intracranial hemorrhage. However, because of their high stroke rate, they appear to benefit from anticoagulant therapy if they have multiple stroke risk factors.

Download full-text

Full-text

Available from: Martha J Radford, Jun 29, 2015
1 Follower
 · 
225 Views
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Purpose. Acute healthcare utilization of stroke and bleeding has been previously examined among patients with nonvalvular atrial fibrillation (NVAF). The long-term cost of such outcomes over several years is not well understood. Methods. Using 1999-2009 Medicare medical and enrollment data, we identified incident NVAF patients without history of stroke or bleeding. Patients were followed from the first occurrence of ischemic stroke, major bleeding, or intracranial hemorrhage (ICH) resulting in hospitalization. Those with events were matched with 1-5 NVAF patients without events. Total incremental costs of events were calculated as the difference between costs for patients with events and matched controls for up to 3 years. Results. Among the 25,465 patients who experienced events, 94.5% were successfully matched. In the first year after event, average incremental costs were $32,900 for ischemic stroke, $23,414 for major bleeding, and $47,640 for ICH. At 3 years after these events, costs remained elevated by $3,156-$5,400 per annum. Conclusion. While the costs of stroke and bleeding among patients with NVAF are most dramatic in the first year, utilization remained elevated at 3 years. Cost consequences extend beyond the initial year after these events and should be accounted for when assessing the cost-effectiveness of treatment regimens for stroke prevention.
    10/2012; 2012:645469. DOI:10.1155/2012/645469
  • Source
  • [Show abstract] [Hide abstract]
    ABSTRACT: Vorhofflimmern ist die häufigste Herzrhythmusstörung bei geriatrischen Patienten, die Prävalenz bei über 80-Jährigen beträgt etwa 10%. Patienten mit Vorhofflimmern haben ein doppelt so hohes Mortalitätsrisiko, das Risiko für einen Schlaganfall ist um den Faktor 5 erhöht. Im Gegensatz dazu stehen die aktuellen Leitlinien der Europäischen Kardiologischen Gesellschaft (ESC), die diese Patientengruppe kaum berücksichtigen. Insbesondere mangelt es an Empfehlungen zu alltäglichen Fragen in der klinischen Betreuung dieser Patientengruppe. Ziel der vorliegenden Arbeit ist, für geriatrisch tätige Kolleg(inn)en unter Aufarbeitung der spezifischen Fachliteratur die vorliegende europäische Leitlinie für dieses Patientenkollektiv zu ergänzen. Diskutiert werden die Themenbereiche Rhythmus- versus Frequenzkontrolle, Antikoagulation, Outcome und Prävention, Stürze, Compliance/Adhärenz, Polypharmazie, geriatrisches Assessment, Demenz, Pflegeheimpatienten und Frailty nach Literaturrecherche in PubMed in Hinblick auf den geriatrischen Patienten. Individuelle Aspekte sollten in die Therapiegestaltung einfließen, allerdings darf die Komplexität dieser Patienten nicht zu einer bedingungslosen Individualisierung der Therapie abseits der Leitlinien führen. Denn es gibt zahlreiche Literaturstellen, mit denen sich viele offene Fragen im Zusammenhang mit Vorhofflimmern bei geriatrischen Patienten beantworten lassen.
    Zeitschrift für Gerontologie + Geriatrie 01/2012; 45(1). DOI:10.1007/s00391-011-0268-0 · 1.02 Impact Factor